Innovative regenerative medicines in the EU: a better future in evidence?

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter, Bruce L. Levine, Michael Kalos et al. · New England Journal of Medicine · 2011 · 3.5K citations · Full text

Chimeric Antigen Receptor, Chronic Lymphoid Leukemia, Autoimmune Disease +13

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

Louis P. Garrison, Adrian Towse, Andrew Briggs et al. · Value in Health · 2013 · 298 citations

Risk Assessment, Engineering, Risk Management +9

The Translation of Cell-Based Therapies: Clinical Landscape and Manufacturing Challenges

Thomas R.J. Heathman, Alvin W. Nienow, Mark McCall et al. · Regenerative Medicine · 2015 · 281 citations · Full text

Tissue Engineering, Cell Therapy, Engineering +20

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

H‐G Eichler, LG Baird, Richard Barker et al. · Clinical Pharmacology & Therapeutics · 2015 · 184 citations · Full text

Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency

Jan Regnström, Franz Koenig, B. Aronsson et al. · European Journal of Clinical Pharmacology · 2009 · 123 citations · Full text

European Medicines Agency, Health Economics, Market Authorisation Applications +9